US Stock MarketDetailed Quotes
PTN Palatin Technologies
- 1.4200
- +0.0400+2.90%
Trading Aug 13 11:19 ET
27.51MMarket Cap-522P/E (TTM)
1.4288High1.4100Low14.01KVolume1.4000Open1.3800Pre Close19.87KTurnover0.08%Turnover RatioLossP/E (Static)19.37MShares5.650052wk High17.32P/B24.26MFloat Cap1.290052wk Low--Dividend TTM17.09MShs Float2687.5000Historical High--Div YieldTTM1.36%Amplitude1.2900Historical Low1.4180Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Palatin Technologies Stock Forum
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
Palatin Technologies, Inc. (NYSE American: PTN), a pioneering biopharmaceutical company, has recently made a significant stride in the treatment of obesity by gaining FDA clearance for its Investigational New Drug (IND) application. This clearance allows Palatin to proceed with a Phase 2 clinical study e...
Palatin Announces FDA Clearance of Ind Application for the Co-Administration of Bremelanotide With Tirzepatide (GLP-1) for the Treatment of Obesity
NEWS
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
NEWS
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
In a significant development for millions suffering from Dry Eye Disease (DED), Palatin Technologies, Inc. recently unveiled the results of their Phase 3 PL9643 MELODY-1 clinical trial at the prestigious American Society of Cataract and Refractive Surgery (ASCRS) conference in 2024. The findings mark a promising advancement...
$Palatin Technologies (PTN.US)$ this company is huge opportunity it has massive funding with 6B USD it’s go to the top 100% sure.
my advice is buy
the $Palatin Technologies (PTN.US)$ will go to the point because it has 6B USD funding
now buy this is moment
No comment yet